VRCA
Verrica Pharmaceuticals Inc.
Overview
Verrica Pharmaceuticals develops and commercializes dermatologic medications, including its FDA-approved product YCANTH (VP-102) for molluscum contagiosum in patients age 2+, which the company markets through a specialized U.S. sales force to dermatologists and pediatricians.
Verrica Pharmaceuticals Inc is a Healthcare company operating in Biotechnology with a $96.7M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 11, 2026).
8 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-1210 Q&A exchanges
- Q3 FY2025Earnings2025-11-176 Q&A exchanges
- Q2 FY2025Earnings2025-08-124 Q&A exchanges
- Q4 FY2024Earnings2025-03-1111 Q&A exchanges
- Q2 FY2024Earnings2024-08-1422 Q&A exchanges
- Q1 FY2024Earnings2024-05-1316 Q&A exchanges
- Q4 FY2023Earnings2024-02-2923 Q&A exchanges
- Q3 FY2023Earnings2023-11-0910 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-11EPS— vs $-0.47—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | — | $-0.47 | — | — | — | — | EODHD |
Source: EODHD. VRCA reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks VRCA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.92 | $3.69 | -20.8% | +5.0% | +6.7% |
| Q4 FY2026 | $3.26 | $3.79 | -14.1% | -4.0% | -3.4% |
| Q3 FY2026 | $2.74 | $3.67 | -25.3% | -0.1% | +2.4% |
| Q2 FY2026 | $3.22 | $3.73 | -13.7% | -1.6% | +0.5% |
| Q1 FY2025 | $2.78 | $3.85 | -27.7% | -3.6% | -5.1% |
| Q4 FY2025 | $3.18 | $3.75 | -15.2% | -0.5% | +2.1% |
| Q3 FY2025 | $3.00 | $3.95 | -24.1% | +3.1% | +3.9% |
| Q2 FY2025 | $2.86 | $3.73 | -23.2% | +2.1% | +3.8% |
| Q1 FY2024 | $2.87 | $4.00 | -28.2% | +1.8% | +2.9% |
| Q4 FY2024 | $3.25 | $3.94 | -17.4% | +0.4% | +2.6% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Jayson RiegerCEO1 yr 7 mo4 callsCurrentSample
CEO since 2024 • 6/8 beats (75%) • last guidance raise Q3 FY2026
- John J KirbyCFO1 yr 7 mo4 callsCurrentSample
CFO since 2024 • 6/8 beats (75%) • last guidance cut Q2 FY2026
- David ZawitzCOO1 yr 6 mo1 callCurrentSample
COO since 2024 • 6/8 beats (75%) • last guidance cut Q2 FY2026
- Noah L RosenbergCMO1 yr 3 mo1 callCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last call held guidance Q1 FY2026
- Edward WhiteCEO0 mo4 callsFormerSample
CEO since 2023 • 6/12 beats (50%) • last call held guidance Q2 FY2026
- Terry KohlerCFO1 yr3 callsFormerSample
CFO since 2023 • 5/12 beats (42%) • last call held guidance Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for VRCA.
$ curl https://api.spokenalpha.com/v1/companies/VRCAFAQ
Frequently asked about VRCA
Where can I find Verrica Pharmaceuticals Inc.'s (VRCA) earnings call transcripts?
Spoken Alpha indexes VRCA's earnings call transcripts at https://spokenalpha.com/companies/VRCA. Each call links to attributed speakers and parsed analyst Q&A.
When was Verrica Pharmaceuticals Inc.'s most recent earnings call?
Verrica Pharmaceuticals Inc. (VRCA) held its most recent earnings call on 2026-05-12, covering fiscal Q1 2026.
What sector is VRCA in?
Verrica Pharmaceuticals Inc. (VRCA) operates in the Healthcare sector (Biotechnology industry).